Clinical Trials Logo

Parkinson's Disease (PD) clinical trials

View clinical trials related to Parkinson's Disease (PD).

Filter by:

NCT ID: NCT02202551 Completed - Clinical trials for Parkinson's Disease (PD)

Open-Label Safety Study of ADS-5102 in PD Patients With LID

Start date: July 2014
Phase: Phase 3
Study type: Interventional

This is a 105-week open-label study to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release formulation of amantadine, in Parkinson's Disease (PD) patients with Levodopa Induced Dyskinesia (LID).

NCT ID: NCT02170376 Completed - Clinical trials for Parkinson's Disease (PD)

The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics

Start date: September 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the effect of repeated dosing of once-daily 25, 50 and 75 mg opicapone (OPC, development code BIA 9-1067) on the levodopa pharmacokinetics (PK), in comparison to placebo and 200 mg entacapone (ENT).

NCT ID: NCT02169895 Completed - Clinical trials for Parkinson's Disease (PD)

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide

Start date: September 2008
Phase: Phase 1
Study type: Interventional

To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of immediate-release levodopa/benserazide 100/25 mg (Prolopa® 100-25)

NCT ID: NCT02169479 Completed - Clinical trials for Parkinson's Disease (PD)

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa

Start date: September 2008
Phase: Phase 1
Study type: Interventional

To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of immediate-release levodopa/carbidopa 100/25 mg (Sinemet® 100/25)

NCT ID: NCT02169466 Completed - Clinical trials for Parkinson's Disease (PD)

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide

Start date: January 2009
Phase: Phase 1
Study type: Interventional

To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa 100 mg/benserazide 25 mg (Madopar HBS).

NCT ID: NCT02169453 Completed - Clinical trials for Parkinson's Disease (PD)

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa

Start date: October 2008
Phase: Phase 1
Study type: Interventional

To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa/carbidopa 100/25 mg (Sinemet® CR 100/25)

NCT ID: NCT02169440 Completed - Clinical trials for Parkinson's Disease (PD)

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Start date: June 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate CYP2C9 inhibition by BIA 9-1067 through the assessment of its effect on the pharmacokinetics of S-warfarin, a substrate of CYP2C9.

NCT ID: NCT02169427 Completed - Clinical trials for Parkinson's Disease (PD)

An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites

Start date: March 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the rate and routes of excretion of OPC and the mass balance in urine, faeces and expired air.

NCT ID: NCT02169414 Completed - Clinical trials for Parkinson's Disease (PD)

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

Start date: February 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the effect of BIA 9 1067 (5 mg, 15 mg and 50 mg) in steady-state conditions on the levodopa pharmacokinetics of a single dose of immediate-release levodopa/carbidopa 100/25 mg and of a single dose of immediate-release levodopa/benserazide 100/25 mg.

NCT ID: NCT02103894 Completed - Clinical trials for Parkinson's Disease (PD)

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

Start date: February 2014
Phase: Phase 1
Study type: Interventional

The goal of this study is to assess [18F]MNI-777 PET imaging as a tool to detect tau pathology in the brain of individuals who carry a clinical diagnosis of a tauopathy, including: Alzheimer's Disease (AD),Parkinson's disease (PD) Progressive Supranuclear Palsy (PSP), chronic traumatic encephalopathy (CTE) and Frontal Temporal Dementia (FTD) and age- and gender-matched healthy subjects.